
Nacelle Therapeutics Inc Profile last edited on: 12/27/2006
CAGE: 47ES1
UEI: FEPKCE7F9A97
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Riley
Congr. District: 01
County: Riley
Public Profile
Nacelle Therapeutics Inc develops and commercializes treatments for cystic fibrosis based on research at the University of Kansas Medical Center. Nacelle Therapeutics research team developed a novel family of transmembrane, ion channel forming peptides that show great promise for cystic fibrosis therapy
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2004 | 1 | NIH | $232,945 | |
Project Title: Enhanced Drug Access to Eye Tissues | ||||
2002 | 1 | NIH | $100,000 | |
Project Title: Synthetic Peptide Modulators of Paracellular Conductance | ||||
2002 | 1 | NIH | $195,000 | |
Project Title: Channel Replacement Therapy for Cystic Fibrosis |
Key People / Management
Gary Rabold -- President
John M Tomich
John M Tomich
Company News
There are no news available.